Skip to content

Study · Non-randomized trial · 2007

6 results

[Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].

Zgliczyński W, Zdunowski P

Endokrynologia Polska1 Sept 2007

PMID18058736 (opens in a new tab)PepBankPUB-18058736
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with persistent acromegaly, pegvisomant reduced IGF-1 from 1270+/-229 to 759+/-223 after the first week (40%, p<0.04).

    In plain wordsIn patients with persistent acromegaly, pegvisomant reduced IGF-1 compared with baseline after the first week.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-1 after first week
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 1 weekAs given in this study (human).

    Measurements

    Baseline IGF-1
    1270
    baseline
    IGF-1
    759
    first week
    Reduction
    40%
    first week

    Source sentences

    Summary
    Pegvisomant reduced IGF-1 after first week of therapy from 1270+/-229 to 759+/-223 (40%, p<0.04).
    5 context sentences
    Summary · context
    Material consisted of 10 patients (6 M, 4 F) aged 24-48 with active acromegaly, after neurosurgery, in which OCTR was ineffective in disease control.
    Summary · context
    Patients with glucose metabolism disturbances were assigned to group receiving PEG.
    Summary · context
    Controls were matched for age, sex, disease history, GH and IGF-1 levels.
    Summary · context
    Patients received pegvisomant throughout 12 weeks, then combined therapy with PEG and OCTR-LAR was started for 8 weeks and then OCTR-LAR alone was given for next 8 weeks.
    Summary · context
    Controls were medicated with OCTR-LAR 30 mg each 4 weeks during study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with persistent acromegaly, prolonged pegvisomant treatment further reduced IGF-1.

    In plain wordsIn patients with persistent acromegaly, longer pegvisomant treatment further reduced IGF-1 compared with earlier treatment.

    Peptide
    Pegvisomant
    Outcome
    DecreaseFurther IGF-1 decrease
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Prolonged therapy led to further IGF-1 decrease.
    5 context sentences
    Summary · context
    Material consisted of 10 patients (6 M, 4 F) aged 24-48 with active acromegaly, after neurosurgery, in which OCTR was ineffective in disease control.
    Summary · context
    Patients with glucose metabolism disturbances were assigned to group receiving PEG.
    Summary · context
    Controls were matched for age, sex, disease history, GH and IGF-1 levels.
    Summary · context
    Patients received pegvisomant throughout 12 weeks, then combined therapy with PEG and OCTR-LAR was started for 8 weeks and then OCTR-LAR alone was given for next 8 weeks.
    Summary · context
    Controls were medicated with OCTR-LAR 30 mg each 4 weeks during study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with persistent acromegaly, IGF-1 after pegvisomant was lower at 12 weeks than initially (604 versus 1270 mg/l, p<0.02).

    In plain wordsIn patients with persistent acromegaly, pegvisomant reduced IGF-1 at 12 weeks compared with baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-1 at 12 weeks versus baseline
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    IGF-1
    604 mg/l
    12 weeks
    IGF-1
    1270 mg/l
    initial

    Source sentences

    Summary
    After 12 weeks of treatment IGF-1 was significantly lower in comparison to initial as well as to controls (604 mg/l vs. 1270 and 1330, respectively, p<0.02).
    5 context sentences
    Summary · context
    Material consisted of 10 patients (6 M, 4 F) aged 24-48 with active acromegaly, after neurosurgery, in which OCTR was ineffective in disease control.
    Summary · context
    Patients with glucose metabolism disturbances were assigned to group receiving PEG.
    Summary · context
    Controls were matched for age, sex, disease history, GH and IGF-1 levels.
    Summary · context
    Patients received pegvisomant throughout 12 weeks, then combined therapy with PEG and OCTR-LAR was started for 8 weeks and then OCTR-LAR alone was given for next 8 weeks.
    Summary · context
    Controls were medicated with OCTR-LAR 30 mg each 4 weeks during study.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with persistent acromegaly, IGF-1 at 12 weeks was lower with pegvisomant than in controls (604 versus 1330 mg/l, p<0.02).

    In plain wordsIn patients with persistent acromegaly, pegvisomant produced lower IGF-1 at 12 weeks than OCTR-LAR controls.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-1 at 12 weeks versus controls
    Study

    n: not reported in source

    Comparator
    OCTR-LAR controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    IGF-1
    604 mg/l
    pegvisomant
    IGF-1
    1330 mg/l
    controls

    Source sentences

    Summary
    After 12 weeks of treatment IGF-1 was significantly lower in comparison to initial as well as to controls (604 mg/l vs. 1270 and 1330, respectively, p<0.02).
    5 context sentences
    Summary · context
    Material consisted of 10 patients (6 M, 4 F) aged 24-48 with active acromegaly, after neurosurgery, in which OCTR was ineffective in disease control.
    Summary · context
    Patients with glucose metabolism disturbances were assigned to group receiving PEG.
    Summary · context
    Controls were matched for age, sex, disease history, GH and IGF-1 levels.
    Summary · context
    Patients received pegvisomant throughout 12 weeks, then combined therapy with PEG and OCTR-LAR was started for 8 weeks and then OCTR-LAR alone was given for next 8 weeks.
    Summary · context
    Controls were medicated with OCTR-LAR 30 mg each 4 weeks during study.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with persistent acromegaly, glucose metabolism improved during pegvisomant treatment.

    In plain wordsIn patients with persistent acromegaly, glucose control improved during pegvisomant treatment.

    Peptide
    Pegvisomant
    Outcome
    Direction not reportedGlucose metabolism
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During treatment with pegvisomant improvement of glucose metabolism was seen, as well as decrease in insulin doses required.
    5 context sentences
    Summary · context
    Material consisted of 10 patients (6 M, 4 F) aged 24-48 with active acromegaly, after neurosurgery, in which OCTR was ineffective in disease control.
    Summary · context
    Patients with glucose metabolism disturbances were assigned to group receiving PEG.
    Summary · context
    Controls were matched for age, sex, disease history, GH and IGF-1 levels.
    Summary · context
    Patients received pegvisomant throughout 12 weeks, then combined therapy with PEG and OCTR-LAR was started for 8 weeks and then OCTR-LAR alone was given for next 8 weeks.
    Summary · context
    Controls were medicated with OCTR-LAR 30 mg each 4 weeks during study.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with persistent acromegaly, required insulin doses decreased during pegvisomant treatment.

    In plain wordsIn patients with persistent acromegaly, required insulin doses decreased during pegvisomant treatment.

    Peptide
    Pegvisomant
    Outcome
    DecreaseRequired insulin dose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During treatment with pegvisomant improvement of glucose metabolism was seen, as well as decrease in insulin doses required.
    5 context sentences
    Summary · context
    Material consisted of 10 patients (6 M, 4 F) aged 24-48 with active acromegaly, after neurosurgery, in which OCTR was ineffective in disease control.
    Summary · context
    Patients with glucose metabolism disturbances were assigned to group receiving PEG.
    Summary · context
    Controls were matched for age, sex, disease history, GH and IGF-1 levels.
    Summary · context
    Patients received pegvisomant throughout 12 weeks, then combined therapy with PEG and OCTR-LAR was started for 8 weeks and then OCTR-LAR alone was given for next 8 weeks.
    Summary · context
    Controls were medicated with OCTR-LAR 30 mg each 4 weeks during study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.